Table of Contents
- Real-world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2-q13.1 duplication and deletion syndromes: A multicenter study.
- FAQ
- FAQ
- How effective is highly purified CBD for seizure reduction in patients with 15q11.2-q13.1 duplication and deletion syndromes?
- Which seizure types respond best to CBD treatment in these genetic epilepsy syndromes?
- What is the appropriate patient population for CBD treatment based on this study?
- Are there additional benefits beyond seizure reduction with CBD treatment?
- How long should CBD treatment be continued to assess effectiveness?
Real-world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2-q13.1 duplication and deletion syndromes: A multicenter study.
Highly purified cannabidiol demonstrates meaningful seizure reduction in children and young adults with rare genetic epilepsy syndromes, with nearly two-thirds achieving at least 50% seizure reduction.
This study provides real-world evidence that pharmaceutical-grade CBD can produce clinically meaningful seizure reduction in patients with specific rare genetic epilepsy syndromes. The data suggest differential response patterns, with tonic seizures in duplication syndrome and myoclonic seizures in Angelman syndrome showing particularly robust responses.
These rare genetic syndromes often present with treatment-resistant epilepsy and limited therapeutic options. The study provides clinicians with outcome data specific to these populations, informing treatment decisions for families facing these challenging diagnoses.
| Study Type | Multicenter Retrospective Study |
| Population | 22 patients with 15q11.2-q13.1 duplication or deletion syndromes (12 dup15q, 10 Angelman syndrome), median age 14.5 years |
| Intervention | Highly purified cannabidiol (CBD) |
| Comparator | Pre-treatment seizure frequency |
| Primary Outcome | Seizure frequency reduction |
| Key Finding | 55.7% mean seizure reduction; 63.6% achieved ≥50% reduction, 18.2% achieved seizure freedom |
| Journal | Epilepsia Open |
| Year | 2024 |
For patients with 15q duplication or Angelman syndrome experiencing drug-resistant epilepsy, highly purified CBD represents a viable therapeutic option with reasonable expectation of meaningful seizure reduction. The 21-month follow-up period suggests sustained benefit in this population.
This study cannot establish causation due to its retrospective design and lacks a control group for comparison. It does not provide guidance on optimal dosing protocols or identify predictors of response within these genetic syndromes.
The small sample size limits generalizability, and the retrospective design introduces potential selection and reporting bias. The lack of standardized outcome measures and variable follow-up periods may affect the reliability of the efficacy estimates.
This study adds to the evidence base for CBD in rare epilepsy syndromes but represents preliminary data requiring larger prospective studies. The results suggest reasonable efficacy expectations while highlighting the need for individualized treatment approaches in genetic epilepsies.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
FAQ
How effective is highly purified CBD for seizure reduction in patients with 15q11.2-q13.1 duplication and deletion syndromes?
This multicenter study demonstrated a mean seizure reduction of 55.7% in patients with these rare genetic epilepsy syndromes. Notably, 63.6% of patients achieved at least 50% seizure reduction, 40.9% achieved at least 75% reduction, and 18.2% became seizure-free during the median 21-month follow-up period.
Which seizure types respond best to CBD treatment in these genetic epilepsy syndromes?
The study found that tonic seizures in patients with 15q duplication syndrome (dup15q) showed the most notable reductions with CBD treatment. In patients with Angelman syndrome, myoclonic seizures demonstrated the greatest improvement with CBD therapy.
What is the appropriate patient population for CBD treatment based on this study?
The study included 22 patients with 15q11.2-q13.1 duplication or deletion syndromes, with a median age of 14.5 years at CBD initiation. All patients with dup15q and two patients with Angelman syndrome presented with a Lennox-Gastaut phenotype, suggesting CBD may be particularly beneficial in this treatment-resistant epilepsy presentation.
Are there additional benefits beyond seizure reduction with CBD treatment?
Yes, the study documented broader clinical improvements beyond seizure control. EEG improvement was observed in 7 out of 16 patients, with marked improvement in two dup15q patients, and 72.7% of patients showed clinical improvement on standardized assessment scales.
How long should CBD treatment be continued to assess effectiveness?
Based on this study’s methodology, patients were followed for a median of 21 months (range 14-33 months) to assess treatment response. This suggests that meaningful seizure reduction and clinical benefits can be sustained over extended periods, though individual response may vary and require ongoing monitoring.
